Cantor Fitzgerald Predicts Immunocore FY2026 Earnings

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Immunocore in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($1.25) per share for the year. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. During the same quarter last year, the company earned ($0.49) EPS. The firm's revenue for the quarter was up 33.6% on a year-over-year basis.

Several other analysts also recently commented on IMCR. HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. Morgan Stanley reissued an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price objective for the company. Finally, Oppenheimer increased their target price on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Immunocore currently has an average rating of "Moderate Buy" and an average price target of $58.89.

Immunocore Stock Down 2.7%

Shares of NASDAQ IMCR traded down $0.95 during trading on Tuesday, reaching $34.68. The company had a trading volume of 435,478 shares, compared to its average volume of 363,326. The business's 50-day moving average is $31.06 and its 200 day moving average is $30.31. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The stock has a market cap of $1.74 billion, a PE ratio of -36.50 and a beta of 0.83. Immunocore has a 12-month low of $23.15 and a 12-month high of $41.54.

Insider Activity at Immunocore

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Immunocore during the 4th quarter valued at about $25,000. Oppenheimer Asset Management Inc. bought a new stake in Immunocore during the first quarter valued at approximately $225,000. Checkpoint Capital L.P. bought a new stake in Immunocore during the first quarter valued at approximately $267,000. Banque Transatlantique SA purchased a new stake in Immunocore during the first quarter valued at approximately $278,000. Finally, NEOS Investment Management LLC raised its position in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares during the period. Institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.